ABION Inc. (KOSDAQ:203400)

Market Cap	135.06B
Revenue (ttm)	1.02B
Net Income (ttm)	-31.39B
Shares Out	29.46M
EPS (ttm)	-1,156.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,336
Average Volume	246,835
Open	4,655.00
Previous Close	4,655.00
Day's Range	4,405.00 - 4,725.00
52-Week Range	4,405.00 - 13,100.00
Beta	1.08
RSI	40.47
Earnings Date	Nov 11, 2025

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 48
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2024, ABION's revenue was 759.68 million, a decrease of -40.38% compared to the previous year's 1.27 billion. Losses were -43.38 billion, 48.5% more than in 2023.